Sugi Predict

Sugi Predict / Compounds / SCHEMBL270629

SCHEMBL270629

SCHEMBL270629

O=S(=O)(Cl)Cc1ccccc1C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 1/20 0.50
▸ IDO1 P14902 2/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ ATM Q13315 1/20 0.44
▸ TDP1 Q9NUW8 2/20 0.43
▸ RECQL P46063 1/20 0.43
▸ AR P10275 1/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ POLQ O75417 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31405393 1.00 AKR1B1 (0.50) AKR1B1IDO1NPSR1ALDH1A1KDM4E
SCHEMBL270518 0.84 P2RX7 (0.41) SLC6A2SLC6A4
SCHEMBL28407899 0.82 ALDH1A1 (0.35) AKR1B1NPSR1ALDH1A1KDM4ETDP1
SCHEMBL2879865 0.81 IDO1 (0.44) AKR1B1IDO1NPSR1ALDH1A1KDM4E
SCHEMBL514295 0.81 NPSR1 (0.53) AKR1B1IDO1NPSR1ALDH1A1KDM4E
SCHEMBL2879992 0.81 AKR1B1 (0.50) AKR1B1IDO1NPSR1ALDH1A1KDM4E
SCHEMBL514294 0.81 AKR1B1 (0.50) AKR1B1IDO1NPSR1ALDH1A1KDM4E
SCHEMBL31405344 0.81 IDO1 (0.52) AKR1B1IDO1NPSR1ALDH1A1KDM4E
SCHEMBL2880348 0.81 AKR1B1 (0.50) AKR1B1IDO1NPSR1ALDH1A1KDM4E
SCHEMBL3517919 0.81 IDO1 (0.52) AKR1B1IDO1NPSR1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718605-B1 PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES WYETH CORP (US) 2009-06-17 — — EP claimed
US-7321061-B2 Processes for the preparation of aryl- and heteroaryl-alkylsulfonyl halides WYETH (US) 2008-01-22 — — US claimed
JP-2007523954-A — — 2007-08-23 — — JP claimed
EP-1718605-A1 PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES Wyeth (US) 2006-11-08 — — EP claimed
WO-2005082843-A1 PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES WYETH (US) 2005-09-09 — — WO claimed
US-20050187408-A1 Processes for the preparation of aryl-and heteroaryl-alkylsulfonyl halides WYETH (US) 2005-08-25 — — US claimed
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2024-12-19 — — US disclosed
US-12116351-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2024-10-15 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2022-12-01 — — US disclosed
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors COLLONGES FRANCOIS (FR) 2003-10-30 — — US disclosed
US-6509499-B1 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment MERCK PATENTGESELLSCHAFT MIT (DE) 2003-01-21 — — US disclosed
EP-0804464-B1 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INT INC (US) 2002-05-08 — — EP disclosed
EP-0765339-B1 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS CORVAS INT INC (US) 1999-01-27 — — EP disclosed
WO-1997046207-A2 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1997-12-11 — — WO disclosed
EP-0804464-A1 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1997-11-05 — — EP disclosed
WO-1996018644-A1 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1996-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN AKR1B1 179/4885IDO1 952/4885NPSR1 2334/4885
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 AKR1B1 1481/4885IDO1 1912/4885NPSR1 23/4885
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 AKR1B1 1541/4885IDO1 1876/4885NPSR1 21/4885
US-12116351-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 AKR1B1 1481/4885IDO1 1912/4885NPSR1 23/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN AKR1B1 179/4885IDO1 952/4885NPSR1 2334/4885
US-20050187408-A1 Processes for the preparation of aryl-and heteroaryl-alkylsulfonyl halides ARSA, AHR, STS AKR1B1 390/4885IDO1 832/4885NPSR1 113/4885
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors AKR1B1, ALDOA, AKR1C1 AKR1B1 1/4885IDO1 247/4885NPSR1 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.